CRXT Stock Overview
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States.
+ 1 more risk
Clarus Therapeutics Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.30|
|52 Week High||US$31.24|
|52 Week Low||US$0.26|
|1 Month Change||-26.42%|
|3 Month Change||-50.70%|
|1 Year Change||-97.03%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-97.02%|
Recent News & Updates
|CRXT||US Pharmaceuticals||US Market|
Return vs Industry: CRXT underperformed the US Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: CRXT underperformed the US Market which returned -12.8% over the past year.
|CRXT Average Weekly Movement||15.5%|
|Pharmaceuticals Industry Average Movement||11.8%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CRXT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: CRXT's weekly volatility has decreased from 23% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.
Clarus Therapeutics Holdings Fundamentals Summary
|CRXT fundamental statistics|
Is CRXT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRXT income statement (TTM)|
|Cost of Revenue||US$3.02m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.69|
|Net Profit Margin||-228.33%|
How did CRXT perform over the long term?See historical performance and comparison
Is CRXT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRXT?
Other financial metrics that can be useful for relative valuation.
|What is CRXT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CRXT's PS Ratio compare to its peers?
|CRXT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CANB Can B
PTPI Petros Pharmaceuticals
NBY NovaBay Pharmaceuticals
CRXT Clarus Therapeutics Holdings
Price-To-Sales vs Peers: CRXT is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (3.1x).
Price to Earnings Ratio vs Industry
How does CRXT's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: CRXT is good value based on its Price-To-Sales Ratio (1x) compared to the US Pharmaceuticals industry average (3.8x)
Price to Sales Ratio vs Fair Ratio
What is CRXT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1x|
|Fair PS Ratio||27.6x|
Price-To-Sales vs Fair Ratio: CRXT is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (27.6x).
Share Price vs Fair Value
What is the Fair Price of CRXT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CRXT ($0.3) is trading below our estimate of fair value ($46.33)
Significantly Below Fair Value: CRXT is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Clarus Therapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRXT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRXT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRXT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRXT's revenue (41.9% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: CRXT's revenue (41.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRXT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Clarus Therapeutics Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CRXT is currently unprofitable.
Growing Profit Margin: CRXT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CRXT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CRXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRXT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: CRXT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Clarus Therapeutics Holdings's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CRXT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CRXT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CRXT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CRXT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRXT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CRXT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.6% each year
Discover healthy companies
What is Clarus Therapeutics Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRXT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRXT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRXT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRXT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Robert Dudley (67 yo)
Dr. Robert E. Dudley, Ph.D. has been President, Chief Executive Officer and Director of Clarus Therapeutics Holdings, Inc. since September 9, 2021. Prior thereto, he served as Legacy Clarus’s Chief Executi...
CEO Compensation Analysis
Compensation vs Market: Robert's total compensation ($USD2.48M) is above average for companies of similar size in the US market ($USD767.72K).
Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.
Experienced Management: CRXT's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Experienced Board: CRXT's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Clarus Therapeutics Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Clarus Therapeutics Holdings, Inc.
- Ticker: CRXT
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$15.778m
- Shares outstanding: 52.02m
- Website: https://clarustherapeutics.com
Number of Employees
- Clarus Therapeutics Holdings, Inc.
- 555 Skokie Boulevard
- Suite 340
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/06 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.